Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis

Blood

Volumn 105, Issue 2, 2005, Pages 735-741

  Balandina, Anna ^b   Lécart, Sandrine ^b   Dartevelle, Philippe ^b   Saoudi, Abdelhadi ^b   Berrih Aknin, Sonia ^a  

^a CNRS   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; FAS ANTIGEN; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MYASTHENIA GRAVIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; THYMOCYTE; THYMUS;

EID: 11244291391     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3900     Document Type: Article

References (45)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-1164.
2. Saoudi A, Seddon B, Fowell D, Mason D. The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients. J Exp Med. 1996;184:2393-2398.
3. + suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389-400.
4. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 2001;31:1247-1254.
5. Annunziato F, Cosmi L, Liotta F, et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med. 2002;196:379-387.
6. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303-1310.
7. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193:1295-1302.
8. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294.
9. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
10. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
11. + regulatory T cells. Nat Immunol. 2003;4:330-336.
12. + T regulatory cells. Nat Immunol. 2003;4:337-342.
13. + T cells. J Clin Invest. 2003;112:1437-1443.
14. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002;109:131-140.
15. Putheti P, Morris M, Stawiarz L, et al. Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables. Eur J Neurol. 2003;10:529-535.
16. Putheti P, Pettersson A, Soderstrom M, Link H, Huang YM. Circulating CD4(+)CD25(+) T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J Clin Immunol. 2004;24:155-161.
17. + regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971-979.
18. + T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003;33:215-223.
19. + regulatory T cells deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood. 2004 May 1;103(3):3428-30.
20. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet. 2001;357:2122-2128.
21. Molnar J, Szobor A. Myasthenia gravis: effect of thymectomy in 425 patients. A 15-year experience. Eur J Cardiothorac Surg. 1990;4:8-14.
22. Berrih-Aknin S, Morel E, Raimond F, et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann N Y Acad Sci. 1987;505:50-70.
23. Berrih S, Morel E, Gaud C, Raimond F, Le Brigand H, Bach JF. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology. 1984;34:66-71.
24. Berrih-Aknin S, Cohen-Kaminsky S, Lepage V, Neumann D, Bach JF, Fuchs S. T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J Autoimmun. 1991;4:137-153.
25. Cohen-Kaminsky S, Levasseur P, Binet JP, Berrih-Aknin S. Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: possible role in autoimmune pathogenesis. J Neuroimmunol. 1989;24:75-85.
26. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol. 1990;28:312-319.
27. Melms A, Chrestel S, Schalke BC, et al. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest. 1989;83:785-790.
28. Moulian N, Bidault J, Truffault F, Yamamoto AM, Levasseur P, Berrih-Aknin S. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood. 1997;89:3287-3295.
29. Leprince C, Cohen-Kaminsky S, Berrih-Aknin S, et al. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J Immunol. 1990;145:2115-2122.
30. Kaminski HJ, Fenstermaker RA, Abdul-Karim FW, Clayman J, Ruff RL. Acetylcholine receptor subunit gene expression in thymic tissue. Muscle Nerve. 1993;16:1332-1337.
31. Salmon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J Clin Invest. 1998;101:2340-2350.
32. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol. 1996;157:3752-3760.
33. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol. 1978;9:495-515.
34. Voltz R, Hohlfeld R, Fateh-Moghadam A, et al. Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671. Neurology. 1991;41:1836-1838.
35. high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-1253.
36. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001;98:2736-2744.
37. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194:629-644.
38. Mysler E, Bini P, Drappa J, et al. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J Clin Invest. 1994;93:1029-1034.
39. Ichikawa H, Ota K, Iwata M. Increased Fas antigen on T cells in multiple sclerosis. J Neuroimmunol. 1996;71:125-129.
40. + T cell-mediated suppression by dendritic cells. Science. 2003;299:1033-1036.
41. Cohen-Kaminsky S, Devergne O, Delattre RM, et al. Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Netw. 1993;4:121-132.
42. Chatila TA, Blaeser F, Ho N, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest. 2000;106:R75-81.
43. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18-20.
44. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20-21.
45. Bassuny WM, Ihara K, Sasaki Y, et al. A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics. 2003;55:149-156.